Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05415072 · ClinicalTrials.gov registry record · Phase 1

A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

A Phase 1 study of Metastatic Uveal Melanoma, sponsored by Novartis Pharmaceuticals.

Active
Registry status
Phase 1
Development phase
66
Enrollment target
11
Study locations

NCT05415072 is a Phase 1 study of Metastatic Uveal Melanoma that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 66 participants, below the 128-participant average among 14 other Metastatic Uveal Melanoma trials with a reported enrollment target (48% lower). The trial reports 11 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05415072, a Phase 1 study of Metastatic Uveal Melanoma, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
66 participants
Enrollment target
11
Study locations

Study Summary

This is a FIH, phase I/II, open label, multi-center study of DYP688 as a single agent. The purpose of this study is to characterize the safety, tolerability, and anti-tumor activity of DYP688 as a single agent in patients with metastatic uveal melanoma (MUM) and other melanomas harboring GNAQ/11 mutations.

Conditions Studied

Metastatic Uveal Melanoma

Interventions

  • DRUG DYP688

Study Locations (11)

Other

  • Novartis Investigative Site - Paris
  • Novartis Investigative Site - Essen
  • Novartis Investigative Site - Heidelberg
  • Novartis Investigative Site - Madrid
  • Novartis Investigative Site - Zurich

New York

  • Columbia University Medical Center- New York Presbyterian Onc Dept - New York
  • Memorial Sloane Kettering Cancer Center MSKCC - New York

Massachusetts

  • Massachusetts General Hospital Hematology Oncology - Boston

New South Wales

  • Novartis Investigative Site - Westmead

Victoria

  • Novartis Investigative Site - Melbourne

South Holland

  • Novartis Investigative Site - Leiden

Trial Details

FieldValue
Enrollment Target 66 participants
Start Date 2022-07-04
Est. Completion 2027-10-01
Phase Phase 1

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05415072

The ClinicalTrials.gov registry entry for NCT05415072 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 128-participant average among 14 other Metastatic Uveal Melanoma trials with a reported enrollment target (48% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Uveal Melanoma appearing as the primary indexed condition, and to 1 intervention - of which DYP688 is the first listed.

NCT05415072 reports 11 study locations spanning 6 distinct geographic areas - top geographies include Other, New York, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05415072 about?

NCT05415072 is a clinical study titled "A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas". This is a FIH, phase I/II, open label, multi-center study of DYP688 as a single agent. The purpose of this study is to characterize the safety, tolerability, and anti-tumor activity of DYP688 as a single agent in patients with metastatic uveal melanoma (MUM) and other melanomas harboring GNAQ/11 mut...

What is the current status of trial NCT05415072?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2022-07-04. Estimated completion is 2027-10-01.

What conditions does trial NCT05415072 study?

This clinical trial studies the following conditions: Metastatic Uveal Melanoma.

What interventions are being tested in trial NCT05415072?

The interventions under investigation include: DYP688 (DRUG).

Who is sponsoring clinical trial NCT05415072?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05415072 being conducted?

This trial has 11 study locations across Massachusetts, New York, New South Wales, Victoria, South Holland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Uveal Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Uveal Melanoma

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.